Drug Profile
ABX 203
Alternative Names: ABX-203; Anti-HBV therapeutic vaccine - Abivax/CIGB; CVP-NASVAC; Hepatitis B vaccine - CIGB; NASVACLatest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology; Wittycell
- Developer Abivax; Center for Genetic Engineering and Biotechnology; Heber Biotec; Japan Agency for Medical Research and Development
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants; Natural killer cell receptor agonists; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Hepatitis B
Most Recent Events
- 10 Nov 2023 Updated efficacy data from the phase I/II trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 30 Dec 2022 No development reported - Phase-I/II for Hepatitis B (Treatment-experienced) in Japan (Intranasal)
- 30 Dec 2022 No development reported - Phase-I/II for Hepatitis B in Japan (Intranasal)